A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemor
A phase 3 trial of Ivonescimab in small-cell lung cancer, run by Akeso, now recruiting.
Overview
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy is a phase 3 interventional study registered as NCT07010263 by Akeso, with 560 participants planned, started 2025-06-13 and due to reach its primary completion in 2028-12-31. Interventions recorded: AK112, Placebo. Conditions listed: Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
Shares Ivonescimab, Akeso, Small-cell lung cancer.
- TrialIvonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
Shares Ivonescimab, Akeso, Small-cell lung cancer.
- TrialAK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
Shares Ivonescimab, Akeso, Small-cell lung cancer.
- TrialA Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
Shares Ivonescimab, Akeso.
- TrialAK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer
Shares Ivonescimab, Akeso.
- TrialAK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
Shares Ivonescimab, Akeso, Small-cell lung cancer.
- TrialCombination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer
Shares Ivonescimab, Akeso.
- TrialA Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer
Shares Ivonescimab, Akeso, Small-cell lung cancer.